Gilead Sciences, Inc. vs Tripadvisor Inc Common Stock — how do they compare? Gilead Sciences, Inc. trades at $135.47 (market cap $168.35B), while Tripadvisor Inc Common Stock trades at $11.04 (market cap $1.28B). The key difference: Gilead Sciences, Inc. is far larger — about 131.5× Tripadvisor Inc Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| GILD | TRIP | |
|---|---|---|
Market Cap | $168.35B | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $19.14 |
52-Week Low | $110.56 | $9.24 |
Enterprise Value | $191.42B | $1.33B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →